Please meet all of our Blavatnik Awardees, and watch some of their winning pitch presentations.
TargaCept: An miRNA Target-based Oligonucleotide for the treatment of Uveitis and Other Inflamatory Disorders.
Developing a chemical drug design platform to establish rich intellectual property for a first-in-class therapeutic for the treatment of fibrosis.
Athena Therapeutics: Targetting Cancer at its core.
Combatting Obesity through a novel mechanism.
A novel bone marrow aspiration device that limits blood contamination and maximizes stem cell recovery.
MAEGI Medicine: New Paradigm of Immune Gene Therapy.
Cytosolics: Targeting Cancer Drugs.
NCS1 - A New Target for Wolfram Syndrome.
A novel chemistry approach to target p53 mutation in human cancer. (Co-Pitch with Ya Ha, Ph.D.)
A multi-functional bioadhesive nanoparticle platform that has the potential to revolutionize the suncare industry.
Antibody meditated Gene Editing.
A novel chemistry approach to target p53 mutation in human cancer. (Co-Pitch with Jonathan Ellman, PhD)
Cynaxis: Immunological Approach to Provide Drug Access to the CNS.
Vittix Therapeutics: Curing Idiopathic Pulmonary Fibrosis with Thyroid Hormone Mimetics.
Drugging Fibrodysplasia Ossificans Progressiva. (Pitch By Ashtekar, Kumar)
EliV5: First in class Antifungal Agents.
Breaking toxin propagation in multiple system atrophy.
Intronistat Therapeutics: Nontoxic Antifungals That Target RNA.
Breaking the Vicious Cycle of Inflammation and Cell Death in Sepsis.
A multi-functional bioadhesive nanoparticle platform.
Cell-Permeable Miniature Proteins: Therapeutic proteins for all.
MODA Pharmaceuticals: Targeted Elimination Platform for Pathogenic Extracellular Proteins.
Developing select inhibitors to slow, halt or reverse the course of Alzheimer’s disease.
Developing therapeutics around a novel epigenetic mechanism aimed at end-stage tumors.